Načítá se...
SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
Denosumab (DMAb) is a soluble inhibitor of RANKL and, therefore, does not incorporate into the bone matrix. Consistently, DMAb discontinuation is associated with the reversal of the effects attained with treatment. Concerns have been raised regarding possible increased vertebral fragility following...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552094/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-532 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|